VA Disability Rating for Nontuberculous Mycobacterium Infection (DC 6312)

Diagnostic Code 6312 · 38 CFR §4.88b

What Is It?

Nontuberculous mycobacterium (NTM) infections are caused by mycobacteria species other than tuberculosis, such as Mycobacterium avium complex (MAC), M. kansasii, and M. abscessus. These bacteria are found in soil, water, and dust. NTM infections most commonly affect the lungs but can also involve skin, soft tissues, bones, joints, and lymph nodes. They are often chronic and difficult to treat. The VA rates active NTM infection at 100 percent with a mandatory re-examination after treatment. Recurrence must be confirmed by culture, histopathology, or other diagnostic testing. Residual damage to skin, respiratory, CNS, musculoskeletal, ocular, GI, and genitourinary systems is rated under appropriate body system codes.

Rating Criteria

RatingCriteria
100%Active NTM infection confirmed by culture, histopathology, or other diagnostic testing during treatment. The 100 percent rating continues for the duration of treatment, followed by a mandatory VA examination.
0%No relapse confirmed on follow-up. Residual damage to skin, respiratory, CNS, musculoskeletal, ocular, GI, or genitourinary systems is rated under appropriate body system codes and section 4.88c residuals.

Evidence Needed

Positive mycobacterial culture identifying the NTM species. CT imaging showing disease pattern. Sputum cultures over time. Treatment records documenting multi-drug regimen. Post-treatment imaging and pulmonary function tests.

Frequently Asked Questions

How is NTM different from tuberculosis?

NTM infections are caused by different mycobacteria species. They are not transmitted person-to-person and are acquired from environmental sources. They tend to be more chronic and harder to cure.

Can NTM infections come back after treatment?

Yes. NTM infections have a significant recurrence rate. Recurrence must be confirmed by culture, histopathology, or other diagnostic testing.

What residual lung damage does NTM cause?

NTM can cause bronchiectasis, pulmonary fibrosis, cavitary disease, and nodular disease — all permanent structural changes that reduce lung function.